Macimorelin acetate
Modify Date: 2025-08-26 23:41:02
Macimorelin acetate structure
|
Common Name | Macimorelin acetate | ||
|---|---|---|---|---|
| CAS Number | 945212-59-9 | Molecular Weight | 534.60700 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H34N6O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Macimorelin acetateMacimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS)[1][2][3]. |
| Name | acetic acid,2-amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide |
|---|---|
| Synonym | More Synonyms |
| Description | Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS)[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
GHSR[1] |
| In Vivo | Macimorelin 醋酸酯 (5mg/kg，每日两次，连续 2 周) 可降低 IHKA 小鼠模型的癫痫发作次数和持续时间[2]。 Animal Model: Intrahippocampal kainic acid (IHKA) mouse model[2] Dosage: 5 mg/kg Administration: Intraperitoneal injection (i.p.), twice daily for 2 weeks. Result: Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect. |
| References |
| Molecular Formula | C28H34N6O5 |
|---|---|
| Molecular Weight | 534.60700 |
| Exact Mass | 534.25900 |
| PSA | 192.67000 |
| LogP | 5.15690 |
| InChIKey | WVDSKQXKCDZXLH-OHIDFYLOSA-N |
| SMILES | CC(=O)O.CC(C)(N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(Cc1c[nH]c2ccccc12)NC=O |
| Macimorelin acetate |
| UNII-AQZ1003RMG |
| EP 1572 acetate |
| AEZS-130 |
| ARD 07 acetate |